Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when BNTC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsStanding Risk Factors
- Material Weakness (unchanged) — The filing discloses a prior material weakness in internal controls over share-based compensation, which is a reportable event under SEC rules.
Benitec Biopharma dismisses Baker Tilly, appoints Ernst & Young as auditor
Filed September 24, 2026 · Period ending September 18, 2026 · ~1 min read
Key Changes
-
high
Audit Committee dismissed Baker Tilly as independent auditor effective September 18, 2026, with formal notice on September 21, 2026.
Item 4.01 verify on EDGAR → -
high
Ernst & Young LLP appointed as independent auditor for fiscal year ending June 30, 2027, subject to completing client acceptance.
Item 4.01 verify on EDGAR → -
medium
Baker Tilly's audit reports for fiscal 2026 and 2025 were unqualified with no going concern or other modifications.
Item 4.01 verify on EDGAR → -
medium
No disagreements with Baker Tilly on accounting principles, financial statement disclosure, or audit scope that would have required mention in the audit report.
Item 4.01 verify on EDGAR → -
medium
Previously identified material weakness in share-based compensation controls was remediated as of June 30, 2026.
Item 4.01 verify on EDGAR →
Summary
Benitec Biopharma has replaced its independent auditor, dismissing Baker Tilly and appointing Ernst & Young for the fiscal year ending June 30, 2027. The change was made by the Audit Committee on September 18, 2026, with formal notice to Baker Tilly on September 21, 2026. The company states that Baker Tilly's audit reports for fiscal 2026 and 2025 were unqualified, with no going concern or other modifications, and that there were no disagreements on accounting principles, financial statement disclosure, or audit scope that would have required mention in the audit report.
The filing also discloses that the company had a material weakness in internal controls over share-based compensation, as reported in its fiscal 2025 annual report. The company states that this material weakness was remediated as of June 30, 2026, and that the matter has been discussed with Baker Tilly and authorized for full cooperation with EY. For retail investors, the auditor change appears to be a routine rotation rather than a contentious dismissal, but the prior material weakness is a notable governance item that has now been addressed.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 24, 2026 · How we verify